Expert Interview
A look at the developing BTK inhibitor landscape for CLL and SLL with a primary focus on the the ASH updates from the Phase 3 AMPLIFY study of Acalabrutinib and the Phase1b study of Sonrotoclax-Zanubrutinib combo
Ticker(s): BGNE, AZN, NRIXInstitution: UCI Irvine
- Hematologist and Oncologist, and Associate Professor — Division of Hematology-Oncology, Department of Medicine, UCI School of Medicine.
- Currently manages 200 patients with CLL annually and is familiar with Nurix Therapeutics' BTK degraders NX-2127 and NX-5948.
- Specializes in chronic lymphocytic leukemia and small lymphocytic lymphoma (CLL/SLL), which has been her research focus for more than a decade as a principal investigator of numerous clinical trials of novel agents that have improved the care of these patients.
Are You Interested In These Questions?
Slingshot Insights Explained
- Call Date
- Feb 05, 2025
- Call Time
- 04:00 PM EST
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
